Anaxis Pharma

Vi-Siblin S granulat (orlistat 60 mg) is an oral dietary fibre supplement formulation developed by Lacuna Pharma Pty Ltd for the indication of obesity. Orlistat is a small-molecule lipase inhibitor approved globally across multiple regulatory jurisdictions. The program, designated EP-005, is currently in Phase 2 development status. The latest disclosed milestone indicates a pilot dose-escalation trial with EMP16 in preparation for Phase III, specifically the POEM trial. Orlistat has established regulatory approval in Australia (TGA, PBS-listed since 2004), the European Union (EMA authorisations from 2023–2024 under multiple marketing authorisation holders including CHEPLAPHARM and Haleon), and the United States (FDA-approved under multiple NDAs). The sponsor's strategy appears focused on advancing this formulation through pivotal Phase 3 evaluation to support potential label expansion or market positioning in the obesity therapeutic area.

Obesity represents a significant unmet medical need with growing prevalence globally and substantial morbidity and mortality burden. The competitive landscape for anti-obesity therapeutics has expanded considerably with the approval of GLP-1 receptor agonists (semaglutide, marketed as Wegovy) and other novel mechanisms. Orlistat remains a widely prescribed oral option with a long safety and efficacy track record, though its efficacy is modest compared to newer agents. The Phase 2 POEM trial preparation suggests Lacuna Pharma is positioning this formulation to compete in an increasingly crowded market. The obesity indication represents a large addressable patient population with significant commercial potential. Regulatory approval of this specific formulation could enable market differentiation through improved dosing convenience, tolerability profile, or patient adherence characteristics. The program's advancement to Phase 3 readiness indicates sponsor confidence in the commercial and clinical viability of this approach within the current obesity treatment landscape.

Drug Class: Lipase inhibitor; Alimentary tract and metabolism agent (ATC A08).

Modality: Small molecule.

Route of Administration: Oral (hard capsules, 60 mg).

Mechanism of Action: Orlistat inhibits pancreatic and gastric lipases, reducing dietary fat absorption in the gastrointestinal tract.

Target: Not yet disclosed for this specific program formulation.

Related Therapies: Orlistat is marketed globally under the brand name XENICAL and as the over-the-counter formulation alli (60 mg). First approval in Australia documented 2004-12-01.

Patent Status: Not yet disclosed.

• Approved in Australia (PBS code 4570M; sponsor Pharmaco (Australia) Limited)
• Approved in European Union (EMEA/H/C/000154, EMEA/H/C/000854; authorisation dates 2023–2024)
• Approved in United States (NDAs 020766, 021887)
• Clinical trials ongoing in China (NCT03383068)

United States (FDA): Orlistat approved under NDAs 020766 and 021887 (sponsors CHEPLAPHARM and HALEON US HOLDINGS). Specific approval status of Vi-Siblin S granulat formulation not yet disclosed.

European Union (EMA): Orlistat approved under EMEA/H/C/000154 (CHEPLAPHARM, authorised 2024-12-04) and EMEA/H/C/000854 (Haleon Ireland Dungarvan Limited, authorised 2023-05-10). Specific approval status of Vi-Siblin S granulat formulation not yet disclosed.

Australia (TGA): Orlistat approved and PBS-listed (code 4570M) since 2004-12-01 (sponsor Pharmaco (Australia) Limited). Specific approval status of Vi-Siblin S granulat formulation not yet disclosed.

China (NMPA): Clinical trials ongoing (NCT03383068). Regulatory approval status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

The EP-005 program is currently in Phase 2; regulatory filing timelines and expected approval dates are not yet disclosed.

Strategic Positioning: Lacuna Pharma's advancement of Vi-Siblin S granulat to Phase 3 readiness suggests a strategy to maintain market presence in obesity therapeutics despite competition from superior-efficacy GLP-1 agonists. Orlistat's established safety profile and oral route may appeal to patients unable or unwilling to use injectable therapies.

Competitive Implications: The POEM Phase 3 trial will be critical to differentiate this formulation from existing orlistat products and establish clinical utility relative to newer agents. Success will likely depend on demonstrating improved efficacy, tolerability, or adherence compared to current standards.

Regulatory Catalysts: Phase 3 POEM trial initiation and data readout represent key near-term milestones. Regulatory submissions to FDA, EMA, and other jurisdictions will follow positive Phase 3 results. Label expansion or new indication claims may be pursued depending on trial outcomes.

Market Dynamics: The obesity market continues to expand with increasing prevalence and awareness. However, GLP-1 agonists have rapidly captured market share. Orlistat-based therapies will likely occupy a niche for patients seeking oral, non-injectable options or those with contraindications to GLP-1 therapy.

Unresolved Questions: The mechanism of action, specific target, and formulation rationale (granulat vs. standard capsule) are not yet disclosed. Patent status and freedom-to-operate considerations are unknown. The relationship between EP-005 and Lacuna's existing ARX-NALTREXONE program is unclear.